Pharma Forecast Report

To view this email as a web page, click here.

Managed Healthcare Executive asked experts to weigh in on Trump’s new blueprint to tackle drug market challenges.

Here’s what they said

How the FDA Plans to Encourage More Biosimilar Uptake

The hope is that more biosimilars will lead to more access and more affordable medications, but biosimilar uptake is lagging. Here’s why and how the FDA hopes to fix it.

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.